Logo image of CY4.MI

CY4GATE SPA (CY4.MI) Stock Fundamental Analysis

BIT:CY4 - Euronext Milan - IT0005412504 - Common Stock - Currency: EUR

3.86  +0.02 (+0.65%)

Fundamental Rating

3

Overall CY4 gets a fundamental rating of 3 out of 10. We evaluated CY4 against 94 industry peers in the Software industry. While CY4 seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CY4 is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CY4 has reported negative net income.
In the past year CY4 had a positive cash flow from operations.
CY4 had positive earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CY4 reported negative operating cash flow in multiple years.
CY4.MI Yearly Net Income VS EBIT VS OCF VS FCFCY4.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

1.2 Ratios

CY4's Return On Assets of -14.75% is on the low side compared to the rest of the industry. CY4 is outperformed by 75.53% of its industry peers.
CY4's Return On Equity of -28.80% is on the low side compared to the rest of the industry. CY4 is outperformed by 69.15% of its industry peers.
Industry RankSector Rank
ROA -14.75%
ROE -28.8%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CY4.MI Yearly ROA, ROE, ROICCY4.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

1.3 Margins

CY4 has a worse Gross Margin (49.73%) than 67.02% of its industry peers.
In the last couple of years the Gross Margin of CY4 has grown nicely.
The Profit Margin and Operating Margin are not available for CY4 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y50.92%
CY4.MI Yearly Profit, Operating, Gross MarginsCY4.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

4

2. Health

2.1 Basic Checks

CY4 does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for CY4. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CY4.MI Yearly Shares OutstandingCY4.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
CY4.MI Yearly Total Debt VS Total AssetsCY4.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 0.84, we must say that CY4 is in the distress zone and has some risk of bankruptcy.
CY4's Altman-Z score of 0.84 is on the low side compared to the rest of the industry. CY4 is outperformed by 69.15% of its industry peers.
CY4 has a debt to FCF ratio of 2.17. This is a good value and a sign of high solvency as CY4 would need 2.17 years to pay back of all of its debts.
CY4's Debt to FCF ratio of 2.17 is fine compared to the rest of the industry. CY4 outperforms 64.89% of its industry peers.
CY4 has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
CY4 has a Debt to Equity ratio of 0.36. This is comparable to the rest of the industry: CY4 outperforms 46.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 2.17
Altman-Z 0.84
ROIC/WACCN/A
WACC9.24%
CY4.MI Yearly LT Debt VS Equity VS FCFCY4.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

CY4 has a Current Ratio of 1.86. This is a normal value and indicates that CY4 is financially healthy and should not expect problems in meeting its short term obligations.
CY4 has a Current ratio of 1.86. This is in the better half of the industry: CY4 outperforms 73.40% of its industry peers.
CY4 has a Quick Ratio of 1.84. This is a normal value and indicates that CY4 is financially healthy and should not expect problems in meeting its short term obligations.
CY4's Quick ratio of 1.84 is fine compared to the rest of the industry. CY4 outperforms 73.40% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.84
CY4.MI Yearly Current Assets VS Current LiabilitesCY4.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for CY4 have decreased strongly by -588.90% in the last year.
Looking at the last year, CY4 shows a very strong growth in Revenue. The Revenue has grown by 22.99%.
Measured over the past years, CY4 shows a very strong growth in Revenue. The Revenue has been growing by 66.46% on average per year.
EPS 1Y (TTM)-588.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.94%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y74.28%
Revenue growth 5Y66.46%
Sales Q2Q%47.6%

3.2 Future

CY4 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.30% yearly.
Based on estimates for the next years, CY4 will show a quite strong growth in Revenue. The Revenue will grow by 12.06% on average per year.
EPS Next Y17.38%
EPS Next 2Y26.92%
EPS Next 3Y28.75%
EPS Next 5Y29.3%
Revenue Next Year16.87%
Revenue Next 2Y13.83%
Revenue Next 3Y12.06%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CY4.MI Yearly Revenue VS EstimatesCY4.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
CY4.MI Yearly EPS VS EstimatesCY4.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CY4. In the last year negative earnings were reported.
Also next year CY4 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CY4.MI Price Earnings VS Forward Price EarningsCY4.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CY4 is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.14
EV/EBITDA N/A
CY4.MI Per share dataCY4.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as CY4's earnings are expected to grow with 28.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.92%
EPS Next 3Y28.75%

More info and screens

0

5. Dividend

5.1 Amount

CY4 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CY4GATE SPA

BIT:CY4 (4/25/2025, 7:00:00 PM)

3.86

+0.02 (+0.65%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners13.64%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap90.98M
Analysts86.67
Price Target5.66 (46.63%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP-3.72%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.6%
PT rev (3m)-18.38%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-701.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.03
P/FCF 4.14
P/OCF 3.37
P/B 0.94
P/tB 7.13
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)0.93
FCFY24.18%
OCF(TTM)1.14
OCFY29.64%
SpS3.74
BVpS4.1
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.75%
ROE -28.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.73%
FCFM 24.95%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y50.92%
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 2.17
Debt/EBITDA N/A
Cap/Depr 28.09%
Cap/Sales 5.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.84
Altman-Z 0.84
F-Score3
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)17.19%
Cap/Depr(5y)62.53%
Cap/Sales(3y)3.95%
Cap/Sales(5y)7.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-588.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.94%
EPS Next Y17.38%
EPS Next 2Y26.92%
EPS Next 3Y28.75%
EPS Next 5Y29.3%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y74.28%
Revenue growth 5Y66.46%
Sales Q2Q%47.6%
Revenue Next Year16.87%
Revenue Next 2Y13.83%
Revenue Next 3Y12.06%
Revenue Next 5YN/A
EBIT growth 1Y-3687.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year510.99%
EBIT Next 3Y85.69%
EBIT Next 5Y72.14%
FCF growth 1Y1156.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2178.38%
OCF growth 3YN/A
OCF growth 5YN/A